Merck & Co. is chasing the finish line with its eye on one prize: a world without cancer. | In “From Our Pipeline to the ...

Would you know the difference between a normal cold and one that has turned into something more serious? | Would you know the ...

Samsung Biologics' labor union has another strike in the works after action planned for last month was held up by an ...

Knudsen’s departure will mark the end of a 27-year run at Novo, with Doustdar telling analysts Wednesday that the outgoing ...

Amid surging sales of Rezdiffra, Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership ...

Bristol Myers Squibb Canada is partnering with TANK Worldwide and Ogilvy Health on a new “What Summer Leaves Behind” skin ...

To Bill Sibold, “it’s hard to find a more attractive growth opportunity in biotech” than metabolic dysfunction-associated steatohepatitis (MASH). | To Madrigal CEO Bill Sibold, “it’s hard to find a ...

Biopharma industry veteran Jackie Elbonne, Ph.D., is retiring at the end of the year, leaving Amgen’s top quality spot to her ...

Pfizer's third-quarter performance bested Wall Street estimates thanks to an Eliquis beat and 37% growth from acquired products.

Bayer’s pharmaceutical business may finally be entering a long-awaited growth cycle, but CEO Bill Anderson still can’t quite ...

In “Pit Stops with the Peetes,” the couple, who serve as “Gemtesa Go-Getters,” share how the overactive bladder (OAB) drug has helped them return to one of their favorite activities, road trips, ...

In a pair of recently disclosed reports, the FDA outlined manufacturing concerns at separate facilities run by China's Hansoh ...